Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216172600> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3216172600 endingPage "4680" @default.
- W3216172600 startingPage "4680" @default.
- W3216172600 abstract "Abstract Introduction Although plenty of data exists on efficacy and safety of CLL drugs, their impact on patients' Health-Related Quality of Life (HRQoL) is largely unknown (1-2). Documentation of drug safety via traditional use of adverse events (AE) in hematology is limited if not complemented with Patient-Reported Outcomes (PRO) measures (3-4). Incorporation of HRQoL PROs is now essential to better evaluate risk-benefit of new therapeutic approaches and it is also highly valued by regulatory stakeholders (5). Most PRO data currently available for CLL patients (pts) came from randomized controlled trial settings (6-7), hence limiting generalizability of findings to CLL real-life patients. CHOICE study was designed to investigate CLL patients' QoL and preference towards different treatment profiles through a Discrete Choice Experiment (DCE) methodology in Italy. Due to the timelines of the study, which started in February 2020, the related data offer an insight into patients' perception and worries during the first wave of the COVID-19 pandemic. Methods This cross sectional, multi-center, observational study included CLL patients, treatment naïve during the watch & wait period (W&W) or already TREATED (around 50% each, controlled at site level), who signed the informed consent for study participation. Exclusion criteria were inability to take oral drugs, cognitive disorders that could impair the comprehension of the questionnaires and concomitant treatment for other malignancies. Patients were asked to fill in the following HRQoL questionnaires: EQ-5D-5L, EORTC QLQ-C30 and QLQ CLL-16, as well as a DCE questionnaire, (described elsewhere). Each questionnaire was completed by the patient on a tablet - using an App specifically developed for the study. Results 401 pts were enrolled in Italy in 16 hematology centers (Feb - July 2020); 199 W&W and 196 TREATED pts completed the questionnaires and were included in the evaluable population. Main patients' characteristics are shown in Table 1. 73.7% of TREATED pts were ON-treatment (30.8% were in 1st-line, 69,2% in further lines) and 26.3% were OFF-treatment; the majority of pts (55,6%) were currently treated with a target therapy (Table1). The EQ-5D-5L questionnaire showed no significant differences between groups. In both groups more than 80% of pts reported low values (1 or 2, indicating no or small impact) on all items. Median VAS was 75 for the TREATED group and 80 for the W&W group (0-100; higher scores indicate higher QoL). QLQ C-30 / CLL-16 scores had very similar results between TREATED and W&W pts suggesting a limited impact of CLL on pts QoL. The median (IQR) QoL Scale was 83.3 (67- 83) for TREATED and 83.3 (67- 92) for W&W pts (0-100; all functional scales had high scores, that represent a better level of functioning; all symptoms' scales had low values, representing a less important symptomatology or problem, Figure 1). The main symptoms reported were fatigue, insomnia, pain, and dyspnea, while the main worry was for future health (Figure 1). Distribution of data was statistically different between the 2 groups only for the Role functioning Scale (p=0.024) and the Social Functioning Scale (p=0.003) of QLQ-C30 and for the Infection Scale (p<0.001) of QLQ CLL-16, always with slightly but significantly better results for the W&W group. Conclusions CHOICE study helps to understand the CLL patients' mindset and feeling in the light of the COVID-19 pandemic impact on health care for this category of pts, highlighting their preferences and worries in a large cohort of pts in Italy, allowing a comparison between TREATED and W&W pts. The main limitation of the study was its cross-sectional design, which does not allow us to evaluate any change in QoL neither with respect to the impact of the pandemic, nor to the effects of the treatment, if any. CLL pts showed a good QoL, as confirmed by both EQ-5D-5L and EORTC QLQ C-30 / CLL-16 scores, with very similar results between TREATED and W&W pts (although slightly better results in the W&W vs TREATED group). The results of the present study are consistent with previous reports, and fatigue was the most reported symptom, while worry for future health was the most relevant score in CLL-16 questionnaire. Hospital accesses reduction that was detected during the pandemic might have influenced patients' response, as well as the extreme attention towards the danger of infections, and might have impacted patients' perception on future health. Figure 1 Figure 1. Disclosures Tedeschi: Beigene: Honoraria, Speakers Bureau; AstraZeneca: Honoraria, Speakers Bureau; AbbVie: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau. Gozzetti: Janssen: Honoraria; AbbVie: Honoraria. Reda: Beigene: Consultancy; Astra Zeneca: Consultancy; Abbvie: Consultancy; Janssen: Consultancy. Gualberti: AbbVie: Current Employment. Malgieri: AbbVie: Current Employment. Finsinger: AbbVie: Current Employment." @default.
- W3216172600 created "2021-12-06" @default.
- W3216172600 creator A5008054206 @default.
- W3216172600 creator A5013236194 @default.
- W3216172600 creator A5013435991 @default.
- W3216172600 creator A5018496231 @default.
- W3216172600 creator A5025046711 @default.
- W3216172600 creator A5027648948 @default.
- W3216172600 creator A5031078901 @default.
- W3216172600 creator A5031992080 @default.
- W3216172600 creator A5038163660 @default.
- W3216172600 creator A5044228908 @default.
- W3216172600 creator A5064951929 @default.
- W3216172600 creator A5073282137 @default.
- W3216172600 creator A5073711573 @default.
- W3216172600 date "2021-11-05" @default.
- W3216172600 modified "2023-09-30" @default.
- W3216172600 title "Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic" @default.
- W3216172600 doi "https://doi.org/10.1182/blood-2021-150274" @default.
- W3216172600 hasPublicationYear "2021" @default.
- W3216172600 type Work @default.
- W3216172600 sameAs 3216172600 @default.
- W3216172600 citedByCount "0" @default.
- W3216172600 crossrefType "journal-article" @default.
- W3216172600 hasAuthorship W3216172600A5008054206 @default.
- W3216172600 hasAuthorship W3216172600A5013236194 @default.
- W3216172600 hasAuthorship W3216172600A5013435991 @default.
- W3216172600 hasAuthorship W3216172600A5018496231 @default.
- W3216172600 hasAuthorship W3216172600A5025046711 @default.
- W3216172600 hasAuthorship W3216172600A5027648948 @default.
- W3216172600 hasAuthorship W3216172600A5031078901 @default.
- W3216172600 hasAuthorship W3216172600A5031992080 @default.
- W3216172600 hasAuthorship W3216172600A5038163660 @default.
- W3216172600 hasAuthorship W3216172600A5044228908 @default.
- W3216172600 hasAuthorship W3216172600A5064951929 @default.
- W3216172600 hasAuthorship W3216172600A5073282137 @default.
- W3216172600 hasAuthorship W3216172600A5073711573 @default.
- W3216172600 hasBestOaLocation W32161726001 @default.
- W3216172600 hasConcept C126322002 @default.
- W3216172600 hasConcept C138496976 @default.
- W3216172600 hasConcept C142052008 @default.
- W3216172600 hasConcept C142724271 @default.
- W3216172600 hasConcept C15744967 @default.
- W3216172600 hasConcept C159110408 @default.
- W3216172600 hasConcept C197934379 @default.
- W3216172600 hasConcept C23131810 @default.
- W3216172600 hasConcept C27158222 @default.
- W3216172600 hasConcept C2779951463 @default.
- W3216172600 hasConcept C512399662 @default.
- W3216172600 hasConcept C71924100 @default.
- W3216172600 hasConceptScore W3216172600C126322002 @default.
- W3216172600 hasConceptScore W3216172600C138496976 @default.
- W3216172600 hasConceptScore W3216172600C142052008 @default.
- W3216172600 hasConceptScore W3216172600C142724271 @default.
- W3216172600 hasConceptScore W3216172600C15744967 @default.
- W3216172600 hasConceptScore W3216172600C159110408 @default.
- W3216172600 hasConceptScore W3216172600C197934379 @default.
- W3216172600 hasConceptScore W3216172600C23131810 @default.
- W3216172600 hasConceptScore W3216172600C27158222 @default.
- W3216172600 hasConceptScore W3216172600C2779951463 @default.
- W3216172600 hasConceptScore W3216172600C512399662 @default.
- W3216172600 hasConceptScore W3216172600C71924100 @default.
- W3216172600 hasIssue "Supplement 1" @default.
- W3216172600 hasLocation W32161726001 @default.
- W3216172600 hasLocation W32161726002 @default.
- W3216172600 hasOpenAccess W3216172600 @default.
- W3216172600 hasPrimaryLocation W32161726001 @default.
- W3216172600 hasRelatedWork W1992727506 @default.
- W3216172600 hasRelatedWork W1993435754 @default.
- W3216172600 hasRelatedWork W2035434084 @default.
- W3216172600 hasRelatedWork W2052963426 @default.
- W3216172600 hasRelatedWork W2085388738 @default.
- W3216172600 hasRelatedWork W2110307640 @default.
- W3216172600 hasRelatedWork W2144706796 @default.
- W3216172600 hasRelatedWork W2168351955 @default.
- W3216172600 hasRelatedWork W2336622019 @default.
- W3216172600 hasRelatedWork W2801469505 @default.
- W3216172600 hasVolume "138" @default.
- W3216172600 isParatext "false" @default.
- W3216172600 isRetracted "false" @default.
- W3216172600 magId "3216172600" @default.
- W3216172600 workType "article" @default.